Is this email not displaying correctly? View it in your browser.
Dear colleagues, partners, and friends,

I would like to thank you for helping DNDi to achieve several important R&D milestones for neglected patients in 2012, from WHO prequalification of ASMQ and its registration in two Asian countries, to the now over 170 million ASAQ treatments delivered to malaria patients in need, to NECT reaching nearly all late-stage sleeping sickness patients in endemic countries in Sub-Saharan Africa. In addition, fexinidazole for sleeping sickness and E1224 for Chagas disease are progressing well in clinical development.

As we enter into a new year, marking a decade since the founding of DNDi, we are – more than ever – convinced of the value of solid partnerships and in keeping patients’ needs in sharp focus.

Everyone connected to DNDi plays a role – be it big or small – in helping us to deliver urgently needed, adapted treatments to neglected patients, and in our efforts to bring entirely new drugs through the pipeline to change the course of certain neglected diseases in the longer term.

We are grateful for the collaboration of partners and the generous support of donors, who make it possible for us to continue our life-saving work.

Best wishes for the new year!

Bernard Pécoul